November 17, 2021

• Press Release: OncoOne and GenScript ProBio Enter Agreement for the Manufacturing of Monoclonal Antibody Drugs Targeting oxMIF

September 13, 2021

• Press Release: OncoOne Appoints Brent Meadows as Chief Business Officer and establishes a U.S. subsidiary as base for strategic partnerships and business development activities.

September, 2021

• OncoOne welcomed our new team members Dr. Sara Sajko, Scientist and  Mert Basaran, Research Associate, who will support our Biotechnology Group.

August, 2021

• OncoOne welcomed Dr. Christine Landlinger-Schubert, Director Preclinical Development & Project Lead Inflammation who will oversee and manage non-clinical studies for our new biotherapeutics.

June 10, 2021

• Press Release: OncoOne Announces Initiation of IND‐Enabling Studies for Lead Program Targeting Oxidized Macrophage Migration Inhibitory Factor and Secures EUR 1M to Explore Potential in Inflammatory Diseases.

May 2021

• The first academic thesis at OncoOne has been completed. Our team member, Gregor Rossmüller, conducted and successfully completed his master’s thesis at OncoOne. He graduated at the University of Natural Resources and Applied Life Sciences (BOKU), Vienna.

April 2021

• We welcomed Friedmund Bachmann, our new Director of CMC Biologics, who will support us in manufacturing, analytics and quality control efforts.

March 2021

• We welcomed our new Scientist, Alejandro Puchol Tarazona to the Biotechnology Group. Alejandro will support the protein engineering activities and protein production.

September 2020

• We welcomed our new Research Associate, Verena Höld to our team. Verena will support our bioengineering and cell biology activities.

September 3, 2020

• Press Release: OncoOne is delighted to announce the formation of our new Scientific Advisory Board. This board will help shape and guide the strategy of OncoOne working closely with the leadership team.

June 2020

• We welcomed our management assistant, Maria Reitzinger to the OncoOne team. Maria will support our CEO in all organisational and administrative tasks.

April, 2020

• We moved our laboratory and office activities to the Vienna BioCenter. The head office remains in Klosterneuburg.

March 18, 2020

• Press Release: OncoOne Launches with EUR 13 Million Series A to Develop Multiple Drug Modalities for Unexplored Target.

December 2019

• We welcomed our new Research Associate, Julia Mayer to the OncoOne team. Julia will support our cell biology activities.

October 2019

• We welcomed Irina Mirkina to our team. Irina (Senior Scientist) will support bioengineering and cell biology activities.

May 2019

• Our CEO, Randolf Kerschbaumer represented OncoOne at this year’s Golden Ribbon Run in Klosterneuburg. The Golden Ribbon Run is all about drawing attention to the joint fight against childhood cancer and all the money raised will be donated to Kinderkrebshilfe, the representative for the interests of children and adolescents suffering from cancer and their families, in Austria.

March 2019

• We presented our startup, OncoOne to state councilor, Dr. Petra Bohuslav. We thank Dr. Bohuslav and the Accent Incubator for their interest in our research projects and for the great discussion!

December 2018

• We would like to welcome Gregor Rossmüller to our team. Gregor will support us as Research Associate.

November 2018

• OncoOne received a grant from the leading national funding agency for industrial research and development in Austria, The Austrian Research Promotion Agency (FFG).

October 2018

• OncoOne opened our labs at the University of Natural Resources and Life Sciences, Vienna.

August 2018

• OncoOne received pre-seed funding from the Austria Wirtschaftsservice Gesellschaft (AWS).
• OncoOne was accepted by the Accent Incubator board to participate in the incubator program of Lower Austria.

June 2018

• OncoOne was founded by Randolf Kerschbaumer, Michael Thiele and Alexander Schinagl.

October 4-6, 2021, Cambridge Healthtech Institute’s 9th Annual Immuno-Oncology Summit, Boston

• Meet our new CBO, Brent Meadows, at CHI’s 9th Annual Immuno-Oncology Summit in Boston to learn more about OncoOne’s pipeline of novel, anti-cancer therapies for the treatment of solid tumors and inflammation. Please visit OncoOne at poster #6 entitled “Harnessing oxidized macrophage migration inhibitory factor (oxMIF) as a druggable isoform of MIF for targeted anticancer therapies”.
• To view the virtual poster presentation by OncoOne’s CSO, Michael Thiele, please click here.

September 6–7, 2021, Biologics UK

• Meet our CTO, Alexander Schinagl at the Biologics UK, London to learn more about OncoOne’s mission to develop novel, anti-cancer therapies for the treatment of solid tumors.

March 22–25, 2021, BIO-Europe Spring Digital Event

• Meet our CEO, Randolf Kerschbaumer and CSO, Michael Thiele at the digital BIO-Europe Spring to learn more about OncoOne’s mission to develop novel, anti-cancer therapies for the treatment of solid tumors.

March 23–27, 2020, BIO-Europe Spring Digital Event

• OncoOne’s CEO, Randolf Kerschbaumer and CSO, Michael Thiele will participate in the BIO-Europe Spring digital event.

November 11-13, 2019, BIO-Europe 

• OncoOne’s CEO, Randolf Kerschbaumer and COO, Michael Thiele will attend BIO-Europe in Hamburg, Germany.

October 17-18, 2019, 4th Drug Discovery Strategic Summit 

• Meet OncoOne’s COO, Michael Thiele at the 4th Drug Discovery Strategic Summit in Munich, Germany.

May 23-24, 2019, 3rd Drug Discovery Nexus Summit 

• Meet OncoOne’s CEO, Randolf Kerschbaumer at the 3rd Drug Discovery Nexus Summit in Munich, Germany.

March 25-27, 2019, BIO-Europe Spring 

• Meet OncoOne’s CEO, Randolf Kerschbaumer at the BIO-Europe Spring in Vienna, Austria.

March 13, 2019,  Oncology Strategy Meeting Europe 2019

• Meet OncoOne’s CEO, Randolf Kerschbaumer at the Oncology Strategy Meeting Europe 2019 in Munich, Germany.